Ledipasvir/sofosbuvir fixed-dose combination for treatment of hepatitis C virus genotype 4 infection.
Hepatitis C virus (HCV) genotype 4 accounts for 8-13% of all chronic HCV infections worldwide. Patients with HCV genotype 4 have been reported to have poor treatment responses to PEGylated interferon and ribavirin regimens. Recently a single tablet, fixed-dose combination of sofosbuvir, an RNA-directed RNA polymerase (NS5B) inhibitor, and ledipasvir, a nonstructural protein 5A (NS5A) inhibitor, has been approved for treatment of chronic HCV infection. Two studies using the fixed-dose combination in chronic HCV genotype 4 for 12 weeks reported sustained virologic response rates at 12 weeks (SVR12) of 93-95%. Data also support the use of ledipasvir/sofosbuvir in chronic HCV genotype 4 and HIV co-infection. Administered as a single once-daily oral regimen, this ribavirin- and interferon-free regimen is well tolerated, with low potential for adverse effects and represents a significant advancement in the treatment of chronic HCV genotype 4 infection.
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
V
V
Nehra
Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
E M
EM
Tan
Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota, USA.
S A
SA
Rizza
Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota, USA. temesgen.zelalem@mayo.edu.
Z
Z
Temesgen
D000998:Antiviral Agents / Q000008:administration & dosage*; D001562:Benzimidazoles / Q000008:administration & dosage*; D002986:Clinical Trials as Topic; D004338:Drug Combinations; D004347:Drug Interactions; D005449:Fluorenes / Q000008:administration & dosage*; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D000069474:Sofosbuvir / Q000008:administration & dosage*
D000998:Antiviral Agents; D001562:Benzimidazoles; D004338:Drug Combinations; D005449:Fluorenes; C586541:ledipasvir; D000069474:Sofosbuvir
Fixed-dose combination; HCV nonstructural protein 5A (NS5A) inhibitors; Hepatitis C virus; Ledipasvir/sofosbuvir; RNA-directed RNA polymerase (NS5B) inhibitors